Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (507) 507
Patent (6) 6
Book / eBook (5) 5
Book Chapter (4) 4
Publication (3) 3
Streaming Video (2) 2
Web Resource (2) 2
Conference Proceeding (1) 1
Government Document (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (263) 263
life sciences & biomedicine (233) 233
humans (211) 211
hematology (128) 128
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (101) 101
oncology (100) 100
imatinib mesylate (84) 84
biological and medical sciences (83) 83
medical sciences (81) 81
benzamides (72) 72
leukemia, myelogenous, chronic, bcr-abl positive - genetics (67) 67
female (63) 63
hemic and lymphatic diseases (63) 63
abridged index medicus (62) 62
fusion proteins, bcr-abl - genetics (62) 62
hematologic and hematopoietic diseases (61) 61
male (60) 60
animals (59) 59
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (57) 57
mutation (54) 54
chronic myeloid leukemia (53) 53
adult (52) 52
middle aged (51) 51
antineoplastic agents (48) 48
antineoplastic agents - therapeutic use (47) 47
protein kinase inhibitors - therapeutic use (47) 47
mice (46) 46
aged (45) 45
protein kinase inhibitors - pharmacology (45) 45
leukemia (42) 42
pyrimidines - pharmacology (42) 42
pyrimidines - therapeutic use (40) 40
piperazines - pharmacology (39) 39
piperazines - therapeutic use (38) 38
antineoplastic agents - pharmacology (36) 36
fusion proteins, bcr-abl - antagonists & inhibitors (36) 36
leukemia, myelogenous, chronic, bcr-abl positive - pathology (36) 36
pharmacology. drug treatments (35) 35
drug resistance, neoplasm (33) 33
cell line, tumor (31) 31
protein-tyrosine kinases - antagonists & inhibitors (31) 31
treatment outcome (31) 31
drug therapy (30) 30
fusion proteins, bcr-abl - metabolism (30) 30
imatinib (28) 28
research (28) 28
aged, 80 and over (27) 27
analysis (27) 27
drug resistance, neoplasm - genetics (27) 27
cancer (26) 26
genetic aspects (26) 26
physical sciences (25) 25
tumors (25) 25
tyrosine (24) 24
prognosis (22) 22
leukemia, myelogenous, chronic, bcr-abl positive - enzymology (21) 21
philadelphia chromosome (21) 21
bcr-abl (20) 20
dasatinib (20) 20
care and treatment (19) 19
hematology, oncology and palliative medicine (19) 19
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (19) 19
cell biology (18) 18
chemotherapy (18) 18
apoptosis - drug effects (17) 17
dose-response relationship, drug (17) 17
kinases (17) 17
myeloid leukemia (17) 17
protein structure, tertiary (17) 17
chromosome aberrations (16) 16
cml (16) 16
fusion proteins, bcr-abl (16) 16
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (15) 15
patients (15) 15
antineoplastic agents - administration & dosage (14) 14
follow-up studies (14) 14
fusion proteins, bcr-abl - chemistry (14) 14
health aspects (14) 14
medical genetics (14) 14
myeloid neoplasia (14) 14
neoplasms (14) 14
phosphorylation (14) 14
protein-tyrosine kinases - genetics (14) 14
drug resistance, neoplasm - drug effects (13) 13
geology (13) 13
k562 cells (13) 13
pyrimidines - administration & dosage (13) 13
signal transduction (13) 13
time factors (13) 13
tumor cells, cultured (13) 13
antineoplastic agents - adverse effects (12) 12
cell proliferation - drug effects (12) 12
medicine (12) 12
medicine, research & experimental (12) 12
molecular targeted therapy (12) 12
piperazines - administration & dosage (12) 12
protein kinase inhibitors - adverse effects (12) 12
proteins (12) 12
research & experimental medicine (12) 12
stem cells (12) 12
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Turning the tide in myelodysplastic/myeloproliferative neoplasms
by Deininger, Michael W.N and Tyner, Jeffrey W and Solary, Eric
Nature reviews. Cancer, ISSN 1474-175X, 07/2017, Volume 17, Issue 7, pp. 425 - 440
Life Sciences & Biomedicine | Oncology | Science & Technology | Myelodysplastic-Myeloproliferative Diseases - epidemiology | Genetic Predisposition to Disease | Prognosis | Myelodysplastic-Myeloproliferative Diseases - therapy | Epigenesis, Genetic | Humans | Gene Expression Regulation, Neoplastic | Hematopoietic Stem Cell Transplantation | Genotype | Myelodysplastic-Myeloproliferative Diseases - genetics | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Inflammation - complications | DNA Methylation | Phenotype | Signal Transduction - drug effects | Adult | Mutation | Child | Care and treatment | Gene mutations | Development and progression | Genetic aspects | Health aspects | Myelodysplastic syndromes | Algorithms | Pathogenesis | Disorders | Bone marrow | Epigenetics | Diagnostic systems | Myelodysplastic syndrome | Neoplasms | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
by O'Hare, Thomas and Walters, Denise K and Stoffregen, Eric P and Jia, Taiping and Manley, Paul W and Mestan, Jürgen and Cowan-Jacob, Sandra W and Lee, Francis Y and Heinrich, Michael C and Deininger, Michael W. N and Druker, Brian J
Cancer research (Chicago, Ill.), ISSN 0008-5472, 06/2005, Volume 65, Issue 11, pp. 4500 - 4505
Life Sciences & Biomedicine | Oncology | Science & Technology | Pharmacology. Drug treatments | Medical genetics | Biological and medical sciences | Medical sciences | Antineoplastic agents | Chromosome aberrations | Tumors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Protein Structure, Tertiary | Cell Line | Dasatinib | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Models, Molecular | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Protein-Tyrosine Kinases - genetics | Animals | Fusion Proteins, bcr-abl | Antineoplastic Agents - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Benzamides | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
by Cortes, Jorge E and Kantarjian, Hagop and Shah, Neil P and Bixby, Dale and Mauro, Michael J and Flinn, Ian and O'Hare, Thomas and Hu, Simin and Narasimhan, Narayana I and Rivera, Victor M and Clackson, Tim and Turner, Christopher D and Haluska, Frank G and Druker, Brian J and Deininger, Michael W.N and Talpaz, Moshe
The New England journal of medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 22, pp. 2075 - 2088
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Amylases - blood | Lipase - blood | Follow-Up Studies | Humans | Middle Aged | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Imidazoles - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Drug Resistance, Neoplasm | Male | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Protein-Tyrosine Kinases - genetics | Antineoplastic Agents - adverse effects | Pyridazines - administration & dosage | Aged, 80 and over | Adult | Female | Pyridazines - adverse effects | Imidazoles - adverse effects | Antineoplastic Agents - chemistry | Pancreatitis - chemically induced | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Patient outcomes | BCR-ABL tyrosine kinase inhibitors | Dosage and administration | Genetic aspects | Acute lymphocytic leukemia | Research | Drug therapy | Tyrosine | BCR protein | Acute lymphatic leukemia | Myeloid leukemia | Leukemia | Pancreatitis | Abl protein | Chronic myeloid leukemia | Lymphatic leukemia | Lipase | Kinases | Philadelphia chromosome | Proteins | Myelosuppression | Fusion protein | Protein-tyrosine kinase | Binding sites | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
by Maxson, Julia E and Gotlib, Jason and Pollyea, Daniel A and Fleischman, Angela G and Agarwal, Anupriya and Eide, Christopher A and Bottomly, Daniel and Wilmot, Beth and McWeeney, Shannon K and Tognon, Cristina E and Pond, J. Blake and Collins, Robert H and Goueli, Basem and Oh, Stephen T and Deininger, Michael W and Chang, Bill H and Loriaux, Marc M and Druker, Brian J and Tyner, Jeffrey W
The New England journal of medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 19, pp. 1781 - 1790
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Leukemia, Neutrophilic, Chronic - diagnosis | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - diagnosis | Humans | Janus Kinases - antagonists & inhibitors | Animals | Receptors, Colony-Stimulating Factor - genetics | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - genetics | Signal Transduction - physiology | Mice | Protein Kinase Inhibitors - pharmacology | RNA, Small Interfering | Leukemia, Neutrophilic, Chronic - genetics | Mutation | Leukemia, Lymphoid - genetics | Protein-Tyrosine Kinases - antagonists & inhibitors | Dasatinib | Care and treatment | Gene mutations | Causes of | Genetic aspects | Dosage and administration | Chronic myeloid leukemia | Diagnosis | Research | Drug therapy | Health aspects | Oncogenes | Tyrosine | BCR protein | Transformation | Myeloid leukemia | Colonies | Leukemia | Colleges & universities | Leukocytes (neutrophilic) | Patients | Lymphoma | Bone marrow | Janus kinase | Colony-stimulating factor | Protein-tyrosine kinase | Adapter proteins | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
by Verstovsek, Srdan and Mesa, Ruben A and Gotlib, Jason and Gupta, Vikas and DiPersio, John F and Catalano, John V and Deininger, Michael W. N and Miller, Carole B and Silver, Richard T and Talpaz, Moshe and Winton, Elliott F and Harvey, Jimmie H and Arcasoy, Murat O and Hexner, Elizabeth O and Lyons, Roger M and Paquette, Ronald and Raza, Azra and Jones, Mark and Kornacki, Deanna and Sun, Kang and Kantarjian, Hagop and COMFORT-I Investigators and COMFORT-I investigators and for the COMFORT-I investigators
Journal of hematology and oncology, ISSN 1756-8722, 02/2017, Volume 10, Issue 1, pp. 1 - 14
JAK | Janus kinase | Myelofibrosis | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Primary Myelofibrosis - mortality | Primary Myelofibrosis - drug therapy | Pyrazoles - therapeutic use | Splenomegaly - drug therapy | Double-Blind Method | Follow-Up Studies | Primary Myelofibrosis - complications | Risk Assessment | Humans | Survival Rate | Treatment Outcome | Fatigue - chemically induced | Diarrhea - chemically induced | Disease Progression | Janus Kinases - antagonists & inhibitors | Pyrazoles - administration & dosage | Sepsis - chemically induced | Pneumonia - chemically induced | Pyrazoles - adverse effects | Treatment outcome | Drug therapy | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
by O'Hare, Thomas and Eide, Christopher A and Deininger, Michael W. N
Blood, ISSN 0006-4971, 10/2007, Volume 110, Issue 7, pp. 2242 - 2249
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Chromosome aberrations | Medical genetics | Recurrence | Cell Proliferation | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Piperazines - chemistry | Pyrimidines - chemistry | Point Mutation - genetics | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Protein Structure, Tertiary | Risk Factors | Models, Molecular | Piperazines - therapeutic use | Mutation - genetics | Imatinib Mesylate | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Animals | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Benzamides | Fusion Proteins, bcr-abl - metabolism | Drug Resistance, Neoplasm - drug effects | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
by Hughes, Timothy P and Mauro, Michael J and Cortes, Jorge E and Minami, Yosuke and Minami, Hironobu and Rea, Delphine and DeAngelo, Daniel J and Breccia, Massimo and Goh, Yeow-Tee and Talpaz, Moshe and Hochhaus, Andreas and le Coutre, Philipp and Ottmann, Oliver and Heinrich, Michael C and Steegmann, Juan L and Deininger, Michael W.N and Janssen, Jeroen J.W.M and Mahon, Francois-Xavier and Yeung, David and Ross, David M and Tallman, Martin S and Park, Jae H and Druker, Brian J and Hynds, David and Duan, Yuyan and Meille, Christophe and Hourcade-Potelleret, Florence and Vanasse, K. Gary and Lang, Fabian and Kim, Dong-Wook
The New England journal of medicine, ISSN 0028-4793, 12/2019, Volume 381, Issue 24, pp. 2315 - 2326
d_article_not_yet_freely_accessible | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Niacinamide - analogs & derivatives | Follow-Up Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Niacinamide - pharmacokinetics | Adult | Female | Antineoplastic Agents - pharmacokinetics | Pyrazoles - pharmacokinetics | Pyrazoles - adverse effects | Niacinamide - adverse effects | Logistic Models | Niacinamide - administration & dosage | Fusion Proteins, bcr-abl - genetics | Pyrazoles - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Aged | Mutation | Tyrosine | Thrombocytopenia | Headache | Myeloid leukemia | Leukemia | Arthralgia | Pancreatitis | Chronic myeloid leukemia | Lipase | Kinases | Patients | Philadelphia chromosome | Side effects | Allosteric properties | Cytogenetics | Protein-tyrosine kinase | Binding sites | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
by O'Hare, Thomas and Shakespeare, William C and Zhu, Xiaotian and Eide, Christopher A and Rivera, Victor M and Wang, Frank and Adrian, Lauren T and Zhou, Tianjun and Huang, Wei-Sheng and Xu, Qihong and Metcalf, Chester A and Tyner, Jeffrey W and Loriaux, Marc M and Corbin, Amie S and Wardwell, Scott and Ning, Yaoyu and Keats, Jeffrey A and Wang, Yihan and Sundaramoorthi, Raji and Thomas, Mathew and Zhou, Dong and Snodgrass, Joseph and Commodore, Lois and Sawyer, Tomi K and Dalgarno, David C and Deininger, Michael W.N and Druker, Brian J and Clackson, Tim
Cancer cell, ISSN 1535-6108, 2009, Volume 16, Issue 5, pp. 401 - 412
CHEMBIO | HUMDISEASE | Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Pyridazines - pharmacology | Protein Kinase Inhibitors - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Antineoplastic Agents - pharmacology | Fusion Proteins, bcr-abl - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Proto-Oncogene Proteins c-abl - genetics | Cell Growth Processes - drug effects | Proto-Oncogene Proteins c-abl - chemistry | Models, Molecular | Imidazoles - pharmacology | Antineoplastic Agents - chemistry | Mice, SCID | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Animals | Signal Transduction - drug effects | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Proto-Oncogene Proteins c-abl - metabolism | Mice |